VetDC Announces New TANOVEA®-CA1 Publication, State of the Art Presentation at VCS 2017 Annual Conference

VetDC - TANOVEA-CA1 - VCS

FORT COLLINS, Colo.–(BUSINESS WIRE)–VetDC, Inc., the leading veterinary cancer therapeutics company, today announced a new TANOVEA®-CA1 (rabacfosadine for injection) publication in Veterinary & Comparative Oncology.  Data from this publication and several new VetDC-sponsored studies was prominently featured in a State of the Art presentation at the Veterinary Cancer Society (VCS) Annual Conference this past weekend in Portland, Oregon, with nearly 700 veterinary healthcare professionals in attendance.

“VetDC has generated an impressive body of data across multiple studies in over 500 patients which support the broad utility of TANOVEA-CA1 for treating canine lymphoma”, noted Dr. Brenda Phillips, a board-certified veterinary oncologist and clinical investigator at Ethos Veterinary Specialty Hospital in San Diego, CA.  “Based on data from this recent publication, TANOVEA-CA1 will be considered as a first-line rescue agent for the treatment of lymphoma in dogs.”

The full Veterinary and Comparative Oncology publication can be accessed here.

TANOVEA-CA1 (rabacfosadine for injection) is a novel small molecule drug designed to preferentially target and attack rapidly dividing cancer cells implicated in lymphoma.  TANOVEA-CA1 has demonstrated anti-tumor activity in both naïve and relapsed canine lymphoma cases, with a generally well-tolerated safety profile.  TANOVEA-CA1 is administered intravenously every three weeks for up to five doses.

TANOVEA-CA1 is commercially available in the US for purchase by licensed veterinarians.  TANOVEA-CA1 was recently granted conditional approval by the U.S. Food and Drug Administration’s Center for Veterinary Medicine (CVM), making TANOVEA-CA1 the first and only new animal drug indicated for the treatment of lymphoma in dogs.

For additional prescribing, safety, and ordering information, please visit click here.

 

Important Safety Information: TANOVEA®-CA1 (rabacfosadine for injection) is not for use in humans and should be kept out of the reach of children. Wear chemotherapy-resistant gloves to prevent contact with feces, urine, vomit, and saliva of treated dogs for five days following treatment. Rabacfosadine is cytotoxic and can cause birth defects and affect female and male fertility. Pregnant and breast-feeding women should not prepare or administer the product. Serious and sometimes fatal respiratory complications, including pulmonary fibrosis have occurred in dogs treated with TANOVEA®-CA1. Do not use in dogs with pulmonary fibrosis, a history of chronic pulmonary disease that could lead to fibrosis, or in breeds with a predisposition to this condition such as West Highland White Terriers. Use with caution in other terrier breeds. Do not use in dogs that are pregnant, lactating, or intended for breeding. Most common adverse reactions included diarrhea, neutropenia, hyporexia, weight loss, and lethargy.  Please see the package insert for full prescribing information.

 

About VetDC, Inc.

VetDC, a Colorado State University startup company, is dedicated to bringing innovative pet cancer therapeutics to market.  In addition to TANOVEA-CA1 for canine lymphoma, VetDC is developing VDC-597, a novel, dual-acting PI3K/mTOR inhibitor, for multiple veterinary cancers, such as hemangiosarcoma and osteosarcoma.

0 Comments

Please provide us with the following before posting a comment